



914/A

### **High serum nitrite levels as a prognostic marker for severe leptospirosis**

T R G N Fernando<sup>1</sup>, S Rajapakse<sup>2</sup>, S Premawansa<sup>3</sup>, HJ De Silva<sup>4</sup>, A R Wickremesinghe<sup>4</sup>,  
S M Handunnetti<sup>1\*</sup>

<sup>1</sup>*Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo,  
Colombo 03*

<sup>2</sup>*Faculty of Medicine, University of Colombo, Colombo 08*

<sup>3</sup>*Faculty of Science, University of Colombo, Colombo 03*

<sup>4</sup>*Faculty of Medicine, University of Kelaniya, Ragama*

At present, there are no standard prognostic markers related to factors contributing to pathogenesis of severe leptospirosis. The objective of this study was to assess the potential of serum nitrite level as a prognostic marker of disease progression to severity. Laboratory confirmed severe (SL) and mild leptospirosis (ML) patients (SL, n = 60 and ML, n = 60) and non-leptospirosis fever (NLF) patients (n = 60) were selected. Serum nitrite (NO<sub>2</sub><sup>-</sup>) levels were tested in patients using the Griess assay and compared with healthy controls (n = 40). Intra-assay and inter-assay coefficients of variability (%CV), ANOVA, Independent samples t-test, and Mann-Whitney U test were performed and ROC curves were plotted. Both intra-assay %CV (7.363) and Inter-assay %CV (8.619) were within the acceptable range. SL patients had significantly high serum NO<sub>2</sub><sup>-</sup> levels (1.99 ± 1.57 μM) compared to ML (1.14 ± 0.62 μM), NLF (0.86 ± 0.88 μM) and HC (0.84 ± 0.80 μM) (P <0.001). Serum NO<sub>2</sub><sup>-</sup> levels of ML patients were comparable to those of the NLF patients. Comparison of acute and convalescent sera of SL and ML patient (n = 13/group) showed that although the NO<sub>2</sub><sup>-</sup> levels of acute sera were significantly different, they were comparable at the convalescent stage (1.93 ± 1.41 μM and 1.11 ± 0.61 respectively). Among SL patients, the serum NO<sub>2</sub><sup>-</sup> levels decreased significantly from acute to convalescent stage (P = 0.003) whereas in the ML patients NO<sub>2</sub><sup>-</sup> levels in both stages were comparable. Serum NO<sub>2</sub><sup>-</sup> levels were not dependent on the number of days of illness. Area under the curve of ROC (SL vs ML) was 63.5 % with the P value of 0.01. Using a serum nitrite cutoff value of 1.99 μM, the test had a specificity of 90% and a sensitivity of 45% in detecting a case of severe leptospirosis. Serum NO<sub>2</sub><sup>-</sup> levels may be used as a prognostic marker with high specificity, albeit relatively low sensitivity, for developing severe leptospirosis.

Acknowledgements: Financial assistance by National Research Council (NRC-12-077)